CYB003 for Depression

Recruiting in Palo Alto (17 mi)

Overseen byLuan Phan, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Ohio State University

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The goal of this study is to learn how psychedelics may help symptoms of depression and anxiety. Participants with major depressive disorder experiencing symptoms of depression and anxiety will receive one dose of either a drug related to psilocybin or a placebo. Assessments include interviews, self-report questionnaires, EEG and fMRI to measure symptoms and brain function.

Research Team

Luan Phan, MD

Principal Investigator

Ohio State University

Eligibility Criteria

This trial is for individuals with major depressive disorder who are currently experiencing symptoms of depression and anxiety. Participants must be eligible based on certain health criteria not specified here.

Inclusion Criteria

I was assigned female or male at birth.

Participant has a BMI of 18 to 30 kg/m2 at Screening

I am between 21 and 65 years old.

See 10 more

Exclusion Criteria

My family has a history of mental health issues.

Presence or relevant history of certain medical conditions

QT interval corrected for heart rate >450 msec at Screening

See 27 more

Treatment Details

Interventions

CYB003 (Psychedelic)

Trial OverviewThe study tests a single dose of CYB003, a drug related to psilocybin, against a placebo in treating depression and anxiety. It includes interviews, questionnaires, EEG, and fMRI to evaluate symptoms and brain function.

Participant Groups

2Treatment groups

Experimental Treatment

Placebo Group

Group I: CYB003Experimental Treatment1 Intervention

Participants will receive one dose of CYB003

Group II: PlaceboPlacebo Group1 Intervention

Participants will receive one dose of placebo